Abstract:Background Amyloid plaque is one of the pathological hallmarks of Alzheimer's disease (AD). Anti⁃beta⁃amyloid (Aβ) immunotherapy is effective in removing brain Aβ, but has shown to be associated with detrimental effects. To avoid severe adverse effects such as meningoencephalitis induced by amyloid beta vaccine with adjuvant, and take advantage of amyloid beta antibody's therapeutic effect on Alzheimer's disease sufficiently, our group has developed a new Alzheimer vaccine with mutated amyloid beta 1-42 peptide stimulating dendritic cells (DC). Our previous work has confirmed that DC vaccine can induce adequate anti⁃amyloid beta antibody in PDAPP Tg mice safely and efficiently. The DC vaccine can improve impaired learning and memory in the Alzheimer's animal model, and did not cause microvasculitis, microhemorrhage or meningoencephalitis in the animal model. However, the exact mechanism of immunotherapy which reduces Aβ deposition remains unknown. In this report, we studied the mechanism of the vaccine, thinking that this may have implications for better understanding of the pathogenesis of Alzheimer's disease. Methods A new Alzheimer vaccine with mutated amyloid beta 1-42 peptide stimulating DC which were obtained from C57/B6 mouse bone marrow was developed. Amyloid beta with Freund's adjuvant was inoculated at the same time to act as positive control. After the treatment was done, the samples of brains were collected, fixed, cut. Immunohistochemical staining was performed to observe the expression of the nuclear hormone liver X receptor (LXR), membrane ⁃ bound protein tyrosine phosphatase (CD45), the ATP⁃binding cassette family of active transporters (ABCA1), receptor for advanced glycation end products (RAGE), β⁃site APP⁃cleaving enzyme (BACE) and Aβ in mouse brain tissue. Semi⁃ quantitative analysis was used to defect CA1, CA2, CA3, DG, Rad in hippocampus region and positive neuron in cortex region. Results Aβ was significantly reduced in the experimental group and the positive control group (P = 0.000), but no changes were seen in the negative control group. The levels of LXR, ABCA1, CD45, BACE expression were significantly higher in the PFDM group with DC vaccine treatment and the levels of RAGE were lower than those in the control group. Conclusion The reduction of Aβ via the DC vaccine occurs through multiple factors to achieve a new immune balance. The beneficial results of DC vaccine, which did not produce side effects, may be caused by the LXR/ABCA1 path. DC alone may play an important role in clearing the Aβ to prevent the occurrence of adverse reaction. DOI：10.3969/j.issn.1672⁃6731.2012.03.016

Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer’s Disease Model Mice

Active Immunotherapy with 12-Mer Aβ1-42-like Assembly Vaccine Shows Efficacy in Aged 3×Tg-Ad Mice.

Immunization with Aβ3-10-KLH vaccine improves cognitive function and ameliorates mitochondrial dysfunction and reduces Alzheimer’s disease-like pathology in Tg-APPswe/PSEN1dE9 mice

A pentavalent peptide vaccine elicits Aβ and tau antibodies with prophylactic activity in an Alzheimer's disease mouse model

P2-315: A Novel Biotherapy for the Treatment of Alzheimer's Disease

A Novel Aβ B-Cell Epitope Vaccine (rCV01) for Alzheimer’s Disease Improved Synaptic and Cognitive Functions in 3 × Tg-AD Mice

Improved Synaptic and Cognitive Function in Aged 3 × Tg-AD Mice with Reduced Amyloid-Β after Immunotherapy with a Novel Recombinant 6Aβ15-Tf Chimeric Vaccine.

Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid-β B-cell epitope chimeric protein as subunit vaccine

Active Immunization with DNA Vaccine Reduced Cerebral Inflammation and Improved Cognitive Ability in APP/PS1 Transgenic Mice by In Vivo Electroporation

An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer’s disease: pyroglutamate amyloid beta

Co-immunization with DNA and Protein Mixture: A Safe and Efficacious Immunotherapeutic Strategy for Alzheimer's Disease in PDAPP Mice

PRECLINICAL STUDIES OF NOROVIRUS P PARTICLE-BASED ACTIVE Aβ IMMUNOTHERAPIES FOR ALZHEIMER’S DISEASE

Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid- had distinct effects on neuropathology and cognitive deficits in EAE/AD mice

DNA vaccines targeting amyloid-β oligomer ameliorate cognitive deficits of aged APP/PS1/tau triple-transgenic mouse models of Alzheimer’s disease

Strikingly Reduced Amyloid Burden And Improved Behavioral Performance In Alzheimer'S Disease Mice Immunized With Recombinant Chimeric Vaccines By Hexavalent Foldable A Beta(1-15) Fused To Toxin-Derived Carrier Proteins

Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid‐β had distinct effects on neuropathology and cognitive deficits in EAE/AD mice

Vaccines targeting the primary amino acid sequence and conformational epitope of Aβ had distinct effects on neuropathology and cognitive deficits in EAE/AD mice.

Amyloid-Beta Immunotherapy for the Prevention and Treatment of Alzheimer Disease: Lessons from Mice, Monkeys, and Humans

Efficacy of a Therapeutic Vaccine Using Mutated Β-Amyloid Sensitized Dendritic Cells in Alzheimer’s Mice

The Role of Mutated Amyloid Beta 1⁃42 Stimulating Dendritic Cells in a PDAPP Transgenic Mouse

Norovirus P Particle-Based Active Aβ Immunotherapy Elicits Sufficient Immunogenicity and Improves Cognitive Capacity in a Mouse Model of Alzheimer’s Disease